TCRX
Waltham, MA 02451
US
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ZDRAVESKI ZORAN | A-Award | 350,000 | $1.12 | 2026-01-20 |
| Dworak Leiden | A-Award | 100,000 | $1.12 | 2026-01-20 |
| Louis Chrystal | A-Award | 420,000 | $1.12 | 2026-01-20 |
| Amello Jason | A-Award | 350,000 | $1.12 | 2026-01-20 |
| MacBeath Gavin | A-Award | 1,165,000 | $1.12 | 2026-01-20 |